Content Conference Coverage Conferences IAS 2017
IAS 2017: Switch from Boosted Protease Inhibitor to Dolutegravir Reduces Lipids in People with HIV
- Details
- Category: HIV Treatment
- Created on Thursday, 21 September 2017 00:00
Switching from a boosted protease inhibitor to the integrase inhibitor dolutegravir (Tivicay) was associated with lipid reductions in people with HIV at higher risk of heart disease, according to results of the NEAT 022 study presented at the recent 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris.
IAS 2017: Doravirine Combo Pill Looks Good for Initial HIV Treatment
- Details
- Category: HIV Treatment
- Created on Thursday, 17 August 2017 00:00
A single-tablet regimen containing the next-generation NNRTI doravirine reduced HIV viral load as much as an efavirenz-based coformulation, but it had a more favorable side effect profile, according to results from the DRIVE-AHEAD studypresented at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.
IAS 2017: Trans Women Wary of Antiretroviral Drug and Hormone Interactions
- Details
- Category: HIV Treatment
- Created on Thursday, 17 August 2017 00:00
Transgender women with HIV may be hesitant to use antiretroviral therapy (ART) or not take it as prescribed because of concerns about drug interactions with feminizing hormones, according to a presentation at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.
IAS 2017: Boosted Darunavir Plus Lamivudine Matches 3-Drug Regimen
- Details
- Category: HIV Treatment
- Created on Thursday, 17 August 2017 00:00
A combination of darunavir/ritonavir and lamivudine was just as effective as the same combination plus tenofovir, according to 24-week results from the ANDES study, presented at the recent 9th IAS Conference on HIV Science (IAS 2017) in Paris.
IAS 2017: Acute Kidney Injury Uncommon on Tenofovir, No Link Seen to Bone Breaks
- Details
- Category: HIV Treatment
- Created on Thursday, 17 August 2017 00:00
Doctors need to monitor patients regularly for kidney function if they are taking tenofovir disoproxil fumarate (TDF), especially if combined with ritonavir, according to a report at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.
More Articles...
- IAS 2017: Aim for $90-$90-$90 Target on HIV, Hepatitis, and TB Drug Prices, Study Says
- IAS 2017: People with HIV Are at Risk for Liver Fibrosis and Steatosis
- IAS 2017: Novel Long-Acting Drug Shows Promise for HIV Treatment and PrEP
- IAS 2017: First Protease Inhibitor Combo Pill Maintains Viral Suppression
- IAS 2017: WHO Recommends Urgent Care Package for People with Advanced HIV Disease
- Coverage of the 2017 IAS Conference on HIV Science
- Coverage of the 2017 IAS Conference on HIV Science
- IAS 2017: Long-Acting Cabotegravir + Rilpivirine Looks Good for HIV ART
- IAS 2017: New HIV Integrase Inhibitor Bictegravir Works Well for First-Line Treatment
- IAS 2017: New HIV Infections Halved as Treatment Scales Up in Swaziland
- IAS 2017: TAG Releases Annual HIV, Hepatitis C, and TB Pipeline Report
- IAS 2017: IAS Conference on HIV Science Starts Sunday in Paris
- IAS 2017: Why Curing Cancer May Be Like Curing HIV -- and May Be As Difficult
- IAS 2017: Cancer Research May Offer Clues for HIV Cure Research -- and Vice Versa
- IAS 2017: VRC01 Antibody Can Delay But Not Prevent HIV Rebound
- IAS 2017: South African Child Has Controlled HIV Off Treatment for 8.5 Years
- IAS 2017: Study of Gay Men Shows No Transmissions from Undetectable HIV+ Partners
- IAS 2017: Long-Acting Cabotegravir Shows Promise For HIV Prevention
- IAS 2017: PrEP Still Protected People Who Had Less Sex in Ipergay Study
- IAS 2017: PrEP Use in U.S. Exceeds 100,000 in Gilead Pharmacy Survey
- IAS 2017: Demonstration Projects Explore Feasibility of PrEP for Adolescents in South Africa
- IAS 2017: Medical Male Circumcision for HIV Prevention Has Benefits for Women Too
- IAS 2017: Another HIV Vaccine Efficacy Trial Will Start This Year
- IAS 2017: Improved Cryptococcal Meningitis Treatment Could Save Thousands of Lives
- IAS 2017: World On Track To Reach 90-90-90 Targets for HIV Treatment by 2020
- IAS 2017: Glecaprevir/ Pibrentasvir Effective for People with HIV/HCV Coinfection
- IAS 2017: Hepatitis C treatment is Effective and Feasible in Africa
Web Design and Development by